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Although countless highly penetrant variants have
been associated with Mendelian disorders, the ge-
netic etiologies underlying complex diseases remain
largely unresolved. By mining the medical records of
over 110 million patients, we examine the extent to
which Mendelian variation contributes to complex
disease risk. We detect thousands of associations
betweenMendelian and complex diseases, revealing
a nondegenerate, phenotypic code that links each
complex disorder to a unique collection of Mendelian
loci. Using genome-wide association results, we
demonstrate that common variants associated with
complex diseases are enriched in the genes indi-
cated by this ‘‘Mendelian code.’’ Finally, we detect
hundreds of comorbidity associations among Men-
delian disorders, and we use probabilistic genetic
modeling to demonstrate that Mendelian variants
likely contribute nonadditively to the risk for a subset
of complex diseases. Overall, this study illustrates a
complementary approach for mapping complex dis-
ease loci and provides unique predictions concern-
ing the etiologies of specific diseases.
INTRODUCTION
Clinicians and geneticists have previously observed that rare,
Mendelian disorders, such as thalassemia and cystic fibrosis,70 Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc.certain chromosomal abnormalities (such as Down and Kleinfel-
ter syndromes), and severely deleterious copy-number variants
(CNV) often predispose patients to more common, apparently
nonMendelian diseases. For example, patients with beta-thalas-
semia, Huntington disease and Friederichs ataxia often develop
type 2 diabetes mellitus (De Sanctis et al., 1988; Podolsky et al.,
1972; Ristow, 2004), and carriers of the genetic variants associ-
ated with Lujan-Fryns and DiGeorge (velo-cardio-facial) syn-
dromes display an increased risk for schizophrenia (De Hert
et al., 1996; Sinibaldi et al., 2004). Additionally, bearers of the
16p11.2 microdeletions and microduplications often develop
autism (Kumar et al., 2008; Tabet et al., 2012). In such cases,
the simple and complex diseases have been long suspected of
sharing genetic architecture; whether there is a broader pattern
of such associations, however, remains unclear.
A large and growing number of Mendelian and chromosomal
diseases have been precisely assigned to particular causal
genetic events. Although Mendelian disorders often manifest
many of the same complexities that are associated with multi-
genic diseases, such as incomplete penetrance and genetic
modification (Badano et al., 2006), they remain the best under-
stood in terms of their underlying genetic etiologies. This is
because the variants underlying Mendelian diseases are gener-
ally highly penetrant and nearly unaffected by the environment.
Furthermore, their physiologic effects are often severe, allowing
for very early diagnosis, sometimes even prenatally. Therefore, in
contrast to more complex human disorders, the clinical diag-
nosis of a Mendelian disease reveals unique insight into the
genotype of the affected patient. Consequently, we hypothesize
that statistically significant comorbidities between complex and
Mendelian illnesses represent a type of genetic association, in
Table 1. The Clinical Record Data Sets Utilized in This Study
Data Set Description
Encoding
Type
Number of
Unique Patients
CU Columbia University, 1985–
2003
ICD9 1,505,822
DK Denmark; database covering
most of the country’s
population
ICD10 6,214,312
NYPH New York Presbyterian
Hospital and Columbia
University; 2004–present
ICD9 767,978
SU Stanford University ICD9 806,369
TX University of Texas at
Houston
ICD9 1,599,528
UC University of Chicago ICD9 146,989
USA MarketScan insurance
claims data set
ICD9 99,143,849
MED Medicare database ICD9 13,039,018
Total: 123,223,865
This table provides a brief description, the ICD encoding type, and the
size of each data set. The MED data set was used for comparison and
was not included in the full meta-analysis.which a non-Mendelian phenotype is mapped to the genetic loci
that cause the Mendelian disease.
By analyzing millions of electronic clinical records obtained
from distinct regions of the United States and Denmark, we
demonstrate that such ‘‘transitive’’ genetic associations are
consistent and ubiquitous, yielding insight into the etiology of
complex diseases. Furthermore, we observe that each complex
disease possesses a unique Mendelian disease allelic architec-
ture, creating a nondegenerate code that identifies each illness
by its associated Mendelian loci. In support of our transitive
association hypothesis, we demonstrate that complex disease
genome-wide association signals are specifically enriched
within the genetic loci indicated by this code. Finally, we use
mathematical modeling to demonstrate that the variants under-
lying Mendelian disorders likely interact with one another to
contribute to complex disease risk, highlighting the potential of
clinical data for uncovering complicated genetic architectures.
RESULTS
Clinical Record Analysis
We mined the administrative data associated with millions of
clinical records for evidence of comorbidity among Mendelian
and complex diseases. As a rule, such records are maintained
in order to facilitate patient billing rather than academic research,
and therefore, they may be incomplete and variably biased (van
Walraven and Austin, 2012). However, this does not diminish
their overall utility for making accurate inferences about clinical
phenotypes in large populations. The key to such analyses is
to carefully consider how missing data and biases may affect
the conclusions of the intended research and, if required, intro-
duce appropriate corrections. Becausewe conditioned our infer-
ences on the observed disease incidence counts, our comorbid-
ity estimates did not depend on the accurate estimation of
marginal disease prevalence. Therefore, we assumed a ‘‘missing
at random’’ model for undocumented records that is common
practice for epidemiological studies with uninformatively missing
data (Lyles and Allen, 2002). Finally, we took great care to focus
our data analysis on clearly identifiable phenotypes (see Exper-
imental Procedures), and we detected disease comorbidity
using a sophisticated statistical pipeline that accounted for a
large set of potentially confounding demographic, socioeco-
nomic, and environmental factors (for details, see Extended
Experimental Procedures and Figure S1 available online).
We judged the quality of our statistical inferences by com-
paring the results generated from multiple, distinct clinical data
sets. In the present study, we examined eight data sets, with
the smallest and largest describing approximately 150,000 and
100million unique patients, respectively (see Table 1; Figure 1A).
We found that our estimates of the comorbidity risks for the
complex-Mendelian disease pairs were remarkably consistent
(see Figures 1F and 1G, all correlation p values < 5 3 108),
which is reassuring considering that the data sets represent pop-
ulations in different geographic regions with variable ethnic
structure and disease prevalence (Figures 1B and 1C). Although
the US data set may possibly partially overlap with the smaller,
North American ones (CU, NYPH, SU, TX, and UC), the smaller
data sets should be nearly completely disjoint from one anotherand from DK, indicating that duplicate records do not drive this
result (see Extended Experimental Procedures for a more
detailed treatment of potentially confounding factors). Although
other groups havemined clinical record data sets for disease co-
morbidities in the past (Hidalgo et al., 2009; Lee et al., 2008), the
vast majority of the relationships detected in this study are likely
to be novel, as associations among complex and Mendelian dis-
eases have never been analyzed at this scale (over 100 million
unique patients) (see Figures 1D and 1E for a comparison to pre-
viously published results).
A Nondegenerate Mendelian Phenotypic Code for
Complex Diseases
Figure 2 summarizes all of the significant comorbidities that were
detected among the complex and Mendelian disorders within
our compendium of clinical records (see Table S4 for detailed re-
sults). Each colored cell in the matrix indicates the logarithm of
the relative risk associated with a significant clinical signal, and
the complex diseases are grouped according to our current un-
derstanding of their pathophysiology. Reassuringly, many of the
known comorbidities are replicated within our data set. For
example, we detected significant comorbidity between lipopro-
tein deficiencies and myocardial infarction (Strong and Rader,
2012) and ataxia telangiectasia and breast cancer (Sellers,
1997). However, the majority of the 2,909 associations shown
in Figure 2 have not been previously reported. For example,
our analysis uncovered significant clinical comorbidities
between Marfan syndrome and several neuropsychiatric dis-
eases (autism, bipolar disorder, and depression), and it deter-
mined that fragile X is significantly associated with asthma,
psoriasis, and viral infection, highlighting a potential immune
system dysfunction in these patients (Ashwood et al., 2010).
In Figure 3A, the rows and columns of the comorbidity
matrix have been rearranged such that disorders with similarCell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc. 71
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Figure 1. A Systematic Comparison of the
Eight Clinical Record Data Sets Analyzed
in This Study
(A) The total number of records in each data set,
broken down by gender.
(B and C) The average prevalence for the complex
and Mendelian diseases across the eight data
sets.
(D and E) Using the superset of the discovered
associations (based on the original seven data
sets; see Extended Experimental Procedures for
details), we compared the number of association
signals that were detected in each data set inde-
pendently, depicted as the percentage of all
associations discovered in the union of the seven
data sets (excluding MED): (D) Mendelian-com-
plex and (E) Mendelian-Mendelian associations.
(F) The rank correlation among relative risk esti-
mates (lower diagonal) and disease prevalence
(upper diagonal) for each significantly comorbid
complex-Mendelian disease pair across the eight
distinct data sets.
(G) Scatter plots depicting the relative risk corre-
lations for three pairs of data sets, indicated using
the colored boxes in (F).
See also Tables S2 and S3.comorbidity structure are placed adjacent to one another.
Importantly, this rearrangement demonstrates that each com-
plex disease was comorbid with a diverse and unique combina-
tion of Mendelian phenotypes. Despite extensive variation within
this ‘‘Mendelian code,’’ much of our current understanding of the
pathophysiology of complex diseases is nonetheless recapitu-
lated (see Figure S2). To illustrate, we computed the Euclidean
distance between every pair of shared risk profiles and produced
the neighbor-joining tree (Saitou andNei, 1987) that best approx-
imates this set of statistics (Figure 3B). Not surprisingly, the re-
sulting tree contained many groupings that are highly consistent
with our current knowledge of disease etiology. For example,
autism, intellectual disability, and epilepsy form a tight cluster
in the tree (replicated in 96% of bootstrap pseudosamples),
consistent with previous genetic studies that have uncovered
variants underlying the risk for all three neuropsychiatric traits
(Shinawi et al., 2010).72 Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc.Complex Disease GWA Signals Are
Enriched within the Genetic Loci
Implicated by the Mendelian Code
We conjectured that the significant com-
plex-Mendelian comorbidities displayed
in Figure 2 indicate that the genes and
pathways perturbed in the Mendelian dis-
orders also play a role in the etiology of
the corresponding complex diseases.
Thus, we hypothesized that the ‘‘Mende-
lian code’’ could be used to pinpoint loci
that harbor complex disease-predispos-
ing genetic variants. To test this predic-
tion, we probed legacy genome-wide
association (GWA) results (NIH, 2012)and asked whether common variants associated with the com-
plex diseases were enriched within the loci implicated by the
Mendelian comorbidities. Overall, we observed that complex
disease GWA signals were globally enriched in Mendelian loci
(106 observed, 55.3 expected, 1.92-fold enrichment, p = 4.0 3
1010), an observation that has been previously highlighted by
others (Lupski et al., 2011). Furthermore, when we restricted
our analysis to unique signals only (i.e., removed duplicate sig-
nals that were replicated in subsequent studies), the enrichment
fell to 1.6-fold but remained highly significant (63 observed, 40.4
expected, p = 4.6 3 105). Importantly, complex disease-spe-
cific GWA signals were specifically enriched in the precise loci
indicated by the Mendelian phenotypic code (1.97-fold enrich-
ment, 40 observed, 20.1 expected, p = 5.7 3 105, see Table
S1 for detailed results), suggesting that the comorbidities high-
lighted in Figure 2 reflect a shared complex-Mendelian genetic
architecture. Moreover, the GWA signals enriched in comorbid
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Figure 2. The Significant Comorbidity Relationships among the Complex and Mendelian Disease Pairs
Entries in the matrix indicate the log10-transformed relative risk associated with each significantly comorbid complex-Mendelian disease pair. The complex
phenotypes are grouped by our current understanding of their pathophysiology. The symbols _ and \ indicate male- and female-specific diseases, respectively.
The numerical values underlying each association are provided in Table S4. The statistical procedure for generating these values is outlined in Figure S1.
See also Tables S1, S2, and S3.Mendelian loci weremore likely to be detected inmultiple studies
than those in other genic SNPs, including those that lie within
noncomorbid Mendelian loci (replication rates: 0.8 versus 0.36,
p = 0.026, Mann-Whitney-U test). Overall, these results suggest
that the loci implicated by the Mendelian code are likely to
contain a spectrum of complex disease predisposing variants,
providing testable hypotheses for future gene resequencing
and exome analyses (see Discussion for details).
Mendelian Disorders Share Significant Clinical
Comorbidity
Our analysis generated a surprisingly large number of statisti-
cally significant clinical associations between pairs of Mendelian
disorders (462 after conservative statistical filtering; see
Extended Experimental Procedures; Figure 4, Figures S3 and
S4; Table S5). We propose that these associations representinteractions among genetic variants in distinct Mendelian loci,
and we found that it was possible to map individual interactions
to specific biological hypotheses. As an example, we observed
significant shared risk between fragile X and glycogenosis
(odds ratio = 859.09), and this effect remained highly significant
after controlling for a wide variety of potentially confounding fac-
tors, including disease similarity, age, gender, ethnicity, and
environment (see Extended Experimental Procedures). A link
between fragile X and glycogenosis has been previously pro-
posed in the molecular genetics literature (De Boulle et al.,
1993; Zang et al., 2009), and glycogen metabolism has been
suggested to play an important role in fragile X pathophysiology
and treatment (Min et al., 2009). A few anecdotal cases aside,
however, most of the relationships in Figure 4 represent totally
undocumented interactions among rare and highly deleterious
genetic variants.Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc. 73
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Figure 3. Complex-Mendelian Comorbid-
ities Provide Unique Insight into the Etiology
of Complex Diseases
(A) The data matrix from Figure 2 is reordered such
that similar rows and columns are adjacent to one
another (accomplished using greedy clustering).
(B) The neighbor-joining tree for the complex
phenotypes was constructed from the Euclidean
distances among the relative risks displayed in
Figure 2 and (A). The bootstrap numbers (10,000
replicates) over tree arcs indicate the reliability of
the corresponding partitions, with 100 being the
most reliable and zero the least. The color of the
tree labels is preserved with regard to the group-
ings of the phenotypes depicted in Figure 2.
(C) Heatmap comparing the qualities of fit for the
two multilocus genetic models discussed in the
main text over a range of loci numbers. The value
of the log10-Bayes factor indicates the support for
the combinatorial model in comparison to the
additive model. A log10-Bayes factor of one in-
dicates that, given the data, the combinatorial
model is ten times more likely than is the additive
model. See Figure S5 for a graphical comparison
of the model fits to the complex disease risk data.
See also Tables S1, S2, and S3 and Figure S2.We do acknowledge that some of the apparently significant
comorbidities could be due to confounding factors. First, mis-
coding errors during medical billing could create false signals
of comorbidity. This could happen, for example, if two distinct
physicians examined the same patient but erroneously entered
different billing codes because of the clinical ambiguity of the
Mendelian disease. Second, the co-occurrence of Mendelian
phenotypes could be an artifact of a cryptic population structure.
As a result of assortative mating, some subpopulations could be
enriched with multiple Mendelian diseases, increasing the
apparent rate of rare disease co-occurrence. Although these
biases seem plausible, we do not believe that they contribute
significantly to the comorbidities depicted in Figure 4 for the
following reasons. First, although medical billing errors were
likely present in the data sets, we went great lengths to estimate
and remove their effects (see Extended Experimental Proce-
dures). Second, our statistical analysis procedure included a
variety of demographic and environmental covariates, and we
found that these potential confounders contributed only margin-
ally to the shared risk amongMendelian disorders, casting doubt
on the cryptic population structure hypothesis.
Perhaps more importantly, there are additional, orthogonal
pieces of evidence that indicate that the previous two con-74 Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc.founders are unlikely to contribute perva-
sively toMendelian-Mendelian comorbid-
ity. For example, we found that comorbid
Mendelian disorders, even after removing
all clinically similar disease pairs, tended
to map to genetic loci that are signifi-
cantly more functionally alike than is ex-
pected by chance, as measured by their
distances within a large human genenetwork (Lee et al., 2011) (see Extended Experimental Proce-
dures, p value < 0.00001). This result fits naturally with the theory
of widespread epistasis amongMendelian variants, but it cannot
be easily explained using either of the other two hypotheses.
Additionally, cryptic population structure, billing code errors,
and genetic interactions make very different predictions with
respect to complex disease risk in patients diagnosed with
multiple comorbid Mendelian disorders (see Experimental Pro-
cedures). In the next section, we use probabilistic modeling to
provide direct statistical evidence that the risk for several com-
plex diseases is highly consistent with the genetic modifier
hypothesis described above.
Mendelian Loci Contribute to Complex Disease Risk in a
Nonadditive Manner
Examining the complex disease risk in patients with compound
Mendelian phenotypes offered an additional avenue for assess-
ing the likelihood of the three mechanisms proposed in the
previous section. As a simple example, assume that the relation-
ships in Figure 4 were dominated by miscoding errors. If this
were true, then an individual diagnosed with one comorbid Men-
delian disorder should have the same average risk for the com-
plex disease as an individual diagnosed with two. Instead, we
4.00.0
Absolute Comorbidity Log10-Odds Ratio
Community 1
Community 2
Community 4
Community 3
Community 5
Community 6
Community 7
Community 8
Figure 4. The Significant Comorbidity Relationships Detected among All Pairs of Mendelian Diseases
The upper diagonal of the matrix displays the log10-transformed odds ratios for the significant associations, with grayscale intensity indicating the effect size of
the association. The lower diagonal displays the community structure determined using a network-clustering algorithm (Blondel et al., 2008), with each com-
munity corresponding to a unique color and associations between diseases within the same community colored accordingly. The numerical values underlying
each association are provided in Table S5. The statistical procedure for generating these values is depicted in Figure S3. An unfiltered version of the matrix is
displayed in Figure S4.
See also Tables S2, S3, and S5.observed that individuals diagnosed with two comorbid Mende-
lian phenotypes had a higher average risk for the complex dis-
ease in 62 out of the 65 of the illnesses considered in this study
(p value = 6.2 3 1012, Wilcoxon signed-rank test). Such ana-
lyses provide only indirect evidence for the genetic modifierhypothesis. To provide direct statistical evidence, we formulated
two probabilistic genetic models for complex disease risk in
patients diagnosed with compound Mendelian phenotypes.
The first, termed the additive model (Risch, 1990), is consis-
tent with cryptic population structure and assumes that theCell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc. 75
Mendelian variants contribute independently to complex disease
risk. The second, called the combinatorial model, invokes a sim-
ple mechanism for genetic epistasis among the Mendelian vari-
ants. By fitting each model to the clinical data sets, we formally
tested whether the genetic modifier hypothesis was supported
by the observed risk profiles of the complex diseases.
The two genetic models that we considered share several
assumptions in common. First, both assume that each complex
disease is associated with a set of genetic loci, some of which
are linked to Mendelian phenotypes as well. This assumption
ensures that eachmodel is capable of accounting for the comor-
bidity structure that was observed within the clinical data.
Second, the models assume that the genetic loci under consid-
eration possess only dominant, recessive, or X-linked (haploid)
variants, although the frequency and penetrance of such variants
can vary freely. Third, they assume that the penetrance values
for the complex diseases, at both Mendelian and other loci,
are sampled from some population-level distribution. Similarly,
both models assume that the frequencies of the deleterious
genotypes are sampled from a population-level distribution as
well. Finally, the models assume that the total number of loci
associated with any complex disease is finite and fixed.
The twomodels differed in one important assumption only: the
additive genetic model assumes that the effects of the delete-
rious genotypes contributed independently (additively) to com-
plex disease risk (Risch, 1990), whereas our nonadditive model
breaks this assumption by introducing ‘‘communities’’ of loci.
Essentially, such communities represented loci that normally
function in a coordinated manner, and our nonadditive model
assumes that at least one adverse genetic event must be present
within multiple communities in order to generate significant com-
plex disease risk. Thus, this community-based genetic model re-
quires combinations of particular deleterious genotypes, so we
refer to it as the combinatorial model to differentiate it from other
nonadditive genetic mechanisms. In the present study, the
combinatorial model was constructed to be as simple as
possible and included only two communities of loci.
Although the assumptions outlined above are simple, they
generate two models that make distinctly different predictions
in terms of the average complex disease risk in patients withmul-
tiple comorbid Mendelian phenotypes (see the Extended Exper-
imental Procedures for details). Specifically, the additive model
predicts that the average complex disease risk should increase
linearly as function of the number of comorbidMendelian pheno-
types, whereas the combinatorial model predicts a superlinear
(polynomial) increase. Furthermore, if billing record miscoding
errors were included into the additive model, the increase in
complex disease risk would become sublinear. All three
signatures were visually apparent in the risk profiles for the com-
plex diseases (see Figure S5), although sublinear increases were
rare (approximately 5 out of 65 illnesses). To formally quantify the
evidence in favor of each model, we took a Bayesian approach
and computed their posterior probabilities conditioned on the
clinical data (see Extended Experimental Procedures).
Because of the computational burden associated with fitting
genetic models to over 100 million patients, we selected a repre-
sentative sample of 20 complex diseases for analysis. In prac-
tice, the population-level mean of the genotype frequencies76 Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc.and the total number of complex disease predisposing loci
were not jointly identifiable, so we repeated the model selection
procedure for a range of potential loci numbers (see Experi-
mental Procedures). Eachmodel was clearly favored for a subset
of diseases, but the combinatorial model had stronger overall
support across the entire set (see Figure 3C). For diseases that
displayed a sublinear increase in risk (consistent with possible
miscoding errors), the additive model was supported over the
combinatorial by a wide margin (see diabetes mellitus type II in
Figure S5). Overall, this result provides additional and orthogonal
support for the hypothesis that Mendelian-Mendelian comorbid-
ities were driven by genetic interactions. It also suggests that
certain complex diseases (such as Addisons disease, acute
glomerulonephritis, and malignant brain neoplasms, but not
the two forms of diabetes or bipolar disorder) have a nonadditive
(epistatic) genetic architecture with respect to Mendelian dis-
ease variants.
DISCUSSION
Highly penetrant mutations have not been found for most com-
mon, complex diseases, despite intensive search. Although
rare single-nucleotide and copy-number variants have been
implicated in some complex disorders, including intellectual
disability (Vissers et al., 2010), schizophrenia (Bassett et al.,
2008) and autism (Iossifov et al., 2012), these results appear to
be the exception rather than the norm. The fact that we observed
widespread comorbidity among Mendelian and complex dis-
eases suggests that rare, highly penetrant variants do in fact
play a significant role in complex disease risk, but their delete-
rious effects do not result in single, isolated diseases. Instead,
highly deleterious genetic variants likely induce a variety of path-
ological consequences, consistent with the Mendelian code
displayed in Figures 2 and 3A. Such analysis resonates with
the results of recent genetic dissections of oligogenic traits,
such as Bardet-Biedl syndrome, which appears to harbor a
diverse genetic architecture that produces a variety of clinical
phenotypes (Katsanis et al., 2001; Zaghloul et al., 2010).
In addition to these direct associations, we also observed that
common risk variants associated with complex diseases were
specifically enriched in comorbid Mendelian loci. The most
obvious explanation for this is that some of the patients included
in GWA studies carried genetic variation that predisposed them
to both the Mendelian and complex diseases. However, there
are several reasons to be skeptical of this hypothesis. First, sub-
jects with Mendelian disorders are typically, by design, excluded
from GWAS (Zhao et al., 2010). Second, Mendelian diseases are
rare and have overt clinical presentations, so the unintentional in-
clusion of such carriers in the studies is highly improbable.
Finally, even if the rate of accidental sampling of Mendelian phe-
notypes were aberrantly high, we do not believe that ‘‘synthetic’’
genome-wide associations, in which the detected common var-
iants are in linkage disequilibriumwithMendelian disease alleles,
drive our results (Dickson et al., 2010). As discussed at length by
others (Visscher et al., 2012), numerous empirical and theoretical
analyses are simply not consistent with this interpretation.
As an alternative explanation, we and others (Lupski et al.,
2011) propose that Mendelian genes carry both rare and
common deleterious variants, such that alleles from both ends of
the frequency spectrum contribute to disease risk. Rare, highly
penetrant variants cause Mendelian disorders, whereas com-
mon variants with milder effects contribute to the complex phe-
notypes. By design, GWAS detect only the latter end of the
frequency spectrum, and the former is typically uncovered
through linkage analysis and sequencing. When the Mendelian
and complex phenotypes are similar, we can think of the two dis-
orders as different ends of the same genetic and phenotypic
spectrum, known as the allelic series hypothesis. In fact, there
are several well-documented examples of this phenomenon,
such as the familial and common forms of Parkinsonism and
blood lipid disorders (Manolio et al., 2009).
However, aside from a few special cases, this straightforward
definition of allelic series is not very helpful when explainingMen-
delian and complex phenotypes that are comorbid and share
genetic loci but are biologically dissimilar. For example, asthma
and systemic primary carnitine deficiency share clinical risk and
are both associated with variants in the SLC22A5 locus, but
there is no obvious relationship between the biology underlying
these two diseases. Instead, we suggest a modification to the
allelic series hypothesis that considers the multifactorial nature
of gene function. On one end of the spectrum, we hypothesize
that very rare, Mendelian disease variants completely or nearly
completely abolish all of a gene’s physiological functions. There-
fore, their effects are highly penetrant and pleiotropic, resulting in
overt pathologies (like Mendelian disease), while increasing a
carrier’s risk for a variety of other disorders. On the other end,
less deleteriousmutationsmay perturb the same genes, but their
effects are more limited, perhaps modifying only a subset of a
gene’s functions. In such instances, the resulting deleterious
effects may be quite subtle, allowing the variants to reach rela-
tively high population frequencies. Moreover, their ultimate path-
ological manifestations may be very different than those that are
observed in patients harboring Mendelian variants, reflecting the
different subsets of physiological functions perturbed by each
mutation type.
With this in mind, we hypothesize that the loci underlying
comorbid Mendelian disorders represent strong candidates for
harboring complex disease-predisposing genetic variants with
moderate and weak effects, as the Mendelian associations
have already suggested that the underlying gene is involved in
the pathophysiology of the complex disorder. This theory is sup-
ported by our GWAS enrichment results, but we believe that it
extends to rare variants with larger effects as well. Because
they have already been shown to contain a variety of complex
disease predisposing variants, we propose that the best candi-
dates for testing this hypothesis are perhaps those loci that
were found to contain both common risk and Mendelian
disease-causing variants (see Table S1). Consistent with this
hypothesis, we note that 4 out of the 7 neoplasms for which
GWAS results were available were found to associate with
both common and rare Mendelian genetic variants in the TERT
locus, which encodes the human telomerase reverse transcrip-
tase. Mendelian variants within this locus completely abolish
reverse-transcriptase enzymatic activity, resulting in several
overt, pathological symptoms (combined into a syndrome called
dyskeratosis congenita) (Kirwan and Dokal, 2009). Recently, arare germline variant in the promoter region of TERT was linked
to a familial form of melanoma, although carriers of the allele
may have increased risk for other neoplasms as well (Horn
et al., 2013). In support, somatic variants within the promoter re-
gion of TERT were also found in a variety of human cancer cell
lines (Huang et al., 2013) and solid tumors (Killela et al., 2013).
Such results raise the intriguing possibility that a spectrum of
TERT-associated variants, both rare and common, somatic
and germline, increase one’s risk for neoplastic disease.
Furthermore, our complex-Mendelian comorbidity analysis
predicted that schizophrenia, bipolar disorder, autism, and
depression are all associated with the following four Mendelian
loci: SYNE1, PRPF3, CACNA1C, and PPP2R2B. Consistent
with their hypothesized shared genetic architecture (Cross-
Disorder Group of the Psychiatric Genomics Consortium et al.,
2013), these four loci were also found to harbor common genetic
variants that influence risk for this same set of diseases. Interest-
ingly, exome sequencing in autism patients has uncovered both
de novo and inherited potentially deleterious variants in SYNE1
(O’Roak et al., 2011; Yu et al., 2013). We find this result particu-
larly interesting, as it suggests that these four genes may also
harbor rare variants that predispose carriers to multiple neuro-
psychiatric disorders. If this is correct, then pooling strategies
that combine sequence data from patients with these different,
but related, complex phenotypes could offer a simple approach
for increasing the power to identify rare variants with modest
effects.
In the second part of our study, we discovered approximately
450 comorbidity associations among pairs of Mendelian disor-
ders, suggesting that genetic interactions amongMendelian var-
iants are quite common. Consistent with this hypothesis, we
used genetic modeling to demonstrate that epistatic effects
could be detected in the complex disease risk profiles of patients
diagnosed with multiple, comorbid Mendelian disorders. At the
very least, our results suggest that strongly deleterious variants
have a high propensity for modifying the effects of other delete-
rious alleles in functionally similar genes. However, the existence
of nonadditive effects among rare genetic variants could have
practical consequences as well. For example, undocumented
epistasis among rare variants in distinct loci could negatively
impact the power of targeted resequencing studies.
Although our inference of widespread, nonadditive genetic
effects is novel, the fact that highly penetrant genetic variants
are subject to modification by other alleles that exist in trans is
well known. For example, at first glance, the Mendelian disorder
retinitis pigmentosa appears to follow the ‘‘independent effects’’
assumption of genetic additivity quite well (Parmeggiani, 2011),
as several, highly penetrant mutations in distinct genes have
been associated with the phenotype. However, this disease
was also one of the first Mendelian phenotypes with clearly
demonstrated digenic inheritance (Kajiwara et al., 1994), and
epistatic interactions among multiple loci have been reported
for other Mendelian phenotypes as well, such as Bardet-Biedl
syndrome (Badano et al., 2006). There are also known examples
in which trans genetic variants modify the specific symptoms of
Mendelian disorders. More specifically, several suspected ge-
netic modifiers have been previously identified for cystic fibrosis
(CF) (Cutting, 2010), a recessive disease caused by mutations inCell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc. 77
the CFTR gene. CF patients display a variety of symptoms,
including mucus congestion in the lungs, intestinal obstruction,
diabetes, abnormal gut microflora, and liver disease, and nearly
a dozen loci have been identified that appear to modulate the
strength of these clinical symptoms (Cutting, 2010). For
example, variation in EDNRA appears to affect the pulmonary
function of CF patients, whereasMSRA alleles modulate intesti-
nal obstruction.
In summary, we detected thousands of instances of comor-
bidity between complex-Mendelian and Mendelian-Mendelian
disease pairs. The existence of such associations was not unex-
pected; however, their widespread nature was surprising.
Furthermore, although there is a growing body of evidence that
genetic interactions are common across both Mendelian and
complex traits, such as Alzheimer’s disease (Badano and Katsa-
nis, 2002), facioscapulohumeral dystrophy type 2 (Lemmers
et al., 2012), and Hirschsprungs disease (Wallace and Anderson,
2011), we believe that this is the first instance in which such re-
lationships have been uncovered systematically across multiple
complex diseases. Ultimately, we demonstrate that digital
phenotypic data can be utilized to infer genetic and genomic
architectures, potentially allowing for extensive, novel analyses
in the field of human disease genetics. Moreover, this work
highlights the importance of documenting a wider spectrum of
Mendelian and other disease traits in a very large population of
humans, perhaps the entire United States or even multiple coun-
tries, in order to uncover the pathophysiology associated with
very rare genetic events.
EXPERIMENTAL PROCEDURES
Phenotype Curation and Billing Code Assignments
To identify the clinical phenotypes of interest, we used the disease codes pro-
vided by the International Disease Classification (ICD) system (WHO, 2010)
(see Table 1). The mappings between billing codes (both ICD9 and ICD10)
and diseases were obtained from Rzhetsky et al. (2007) and by manual cura-
tion, first by a PhD-level contractor trained in a biomedical field and second by
two of the authors, iteratively. All billing code mappings for the complex and
Mendelian diseases are provided in Tables S2 and S3, respectively. The billing
codes enabled the identification of 65 specific complex disorders and 95Men-
delian disease groups (representing 213 disorders) (see Tables S2 and S3,
respectively). Note, this reduction of 213-to-95 was not a choice of experi-
mental design but was necessitated by the ICD9 code taxonomy. See
Extended Experimental Procedures for additional details.
Clinical Record Analysis
Each clinical record database was first parsed (see Table 1), removing dupli-
cate records and identifying patients that harbored the diseases of interest.
In theory, a small fraction of these records could be shared between US and
the other, smaller US data sets (CU, NYPH, SU, TX, UC) because some
patients could have been documented in multiple databases. Because dupli-
cate records would strongly bias the results for rare diseases, we decided
against simply combining the information from different data sets into a single
meta-analysis. Instead, we performed an independent statistical analysis for
each data set and then combined the results according to a conservative pro-
cedure (see Extended Experimental Procedures for details). For the complex-
Mendelian comorbidity analysis, any disease pair containing a complex or
Mendelian disease that was specific to males or females (indicated by _ and
\, respectively, in Figure 2) was analyzed after conditioning on the appropriate
gender; gender-specific diseases were not included in the Mendelian-Mende-
lian analysis. The MED data set (Hidalgo et al., 2009; Lee et al., 2008) was
excluded from the meta-analysis, as we were unable to consistently identify78 Cell 155, 70–80, September 26, 2013 ª2013 Elsevier Inc.our phenotypes of interest. Specifically, the MED data set provides individual
ICD9 code counts only, but many of the disorders used in our analysis map to
multiple such codes. Additional details concerning our statistical procedures
for the analysis of complex-Mendelian and Mendelian-Mendelian disease
pairs are provided in the Extended Experimental Procedures.
Neighbor-Joining Tree Inference
The complex disease tree was constructed from the Mendelian comorbidity
relationships using the neighbor-joining method (Saitou and Nei, 1987). See
Extended Experimental Procedures for additional details.
GWAS Enrichment Analysis
To test for an enrichment of common, complex disease risk variants inMende-
lian loci, we aligned legacy genome-wide association results (NIH, 2012) with
the SNP-to-gene annotations provided by SCAN (Gamazon et al., 2010). Bino-
mial tests that specifically controlled for gene length and SNP annotation
biases were used to assess enrichment (see Extended Experimental Proce-
dures for details).
The Additive and Nonadditive Genetic Models for Complex Disease
Risk
In the main text, we briefly described two competing genetic models that
specify distinct mechanisms for how multiple Mendelian disease variants
combine to affect complex disease risk. Ultimately, the additive and combina-
torial models make very different predictions with respect to the increase in
complex disease risk as a function of the number of comorbid Mendelian phe-
notypes, allowing them to be differentiated within our massive clinical data
sets. The mathematical details concerning this prediction are somewhat
involved, and the interested reader should consult the Extended Experimental
Procedures. In the following section, we simply introduce our competing
genetic models using standard notation.
Consistent with common practice (Risch, 1990), each of our genetic models
treats the genotype (g) and phenotype (f) of an individual as random variables.
Their joint probability is equivalent to the expected population frequency of in-
dividuals that possess both a particular genotype (G) and disease of interest
(D). It is computed by taking the product of the genotype frequency and its
corresponding penetrance:
Pðf=D;g=GjQÞ=Pðg=GjQÞPðf=Djg=G;QÞ=FðGÞ3WDðGÞ;
where F(G) is the probability of observing genotypeG andWD(G) is the genetic
penetrance ofGwith respect to phenotype D (i.e., the probability of D givenG)
(Risch, 1990). The overall expected prevalence of the disease within the
population is computed by summing the previous probability over all possible
genotypes:
Pðf=DjQÞ=
X
G
FðGÞ3WDðGÞ:
Although not included for the sake of simplicity, environmental factors can be
easily incorporated into this framework through the inclusion of additional
random variables.
Our additive genetic model is specified within the previous framework by
defining the following simple penetrance function (Risch, 1990):
WDðGÞ= 1
Yn
i = 1
½1WDðGiÞ;
where n is the number of independent loci affecting phenotypeD, andWD(Gi) is
the marginal penetrance function of the genotype at the ith locus (Risch, 1990)
that may take a variety of forms (dominant, recessive, additive, etc.). Techni-
cally, the model assumes that each locus contributes independently to com-
plex disease risk, and this assumption generally underlies most ‘‘additive’’
models in human genetics. That said, it also approximates a stricter definition
of ‘‘additivity,’’ in which the probability of the complex disease is simply the
linear combination of the penetrance probabilities of the individual loci (Risch,
1990).
Our nonadditive genetic model assumes that the deleterious genotypes
belong to a different ‘‘communities’’ of loci that act coordinately, and at least
one adverse genetic event must be present within multiple communities in
order to generate significant complex disease risk. Because this model re-
quires combinations of deleterious alleles, we call it the ‘‘combinatorial’’
model. To illustrate, imagine two disjoint groups of loci, or ‘‘communities,’’
each harboring a set of genotypes that predispose an individual to the disease
of interest. We denote the two communities using circle and square sub-
scripts, such that fgB;1;gB;2; :::; gB;nBg and fg,;1;g,;2; :::; g,;n,g denote
the genetic loci that belong to each community and nB and n, denote com-
munity sizes. To simplify notation, wewill indicate either the square or the circle
community, depending on context, using the C symbol ðC = fB;,gÞ.
Assuming an additive model within each community, the penetrance function
for the two-community combinatorial model is
WDðGÞ=
Y
C˛fB;,g
 
1
YnC
i = 1
½1WDðGiÞ
!
:
Note that more general formulations of the model could allow for more than
two communities and a variety of different community- and loci-specific pene-
trance functions.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, five
figures, and five tables and can be found with this article online at http://dx.
doi.org/10.1016/j.cell.2013.08.030.
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